[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612022":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":48,"collaborators":50,"id":54,"slug":31,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":31,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":31,"enrollmentInfo":62,"targetDuration":31,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":31,"overallStatus":36,"whyStopped":31,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Bioray Laboratories","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","5.0-10×10\\^6cells\u002Fkg",[13],"Drug: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection","The study drug is administered intravenously at a fixed dose within 1-2 days after lymphocyte depletion, and its efficacy and safety are observed.",[9],[21],"BRL-305",[23],{"name":24,"affiliation":25,"role":26},"Ping Li, PhD","13564181131","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":25,"phoneExt":31,"email":32},"Ping Li, phD","CONTACT",null,"lilyforever76@126.com",[34],{"facility":35,"status":36,"city":37,"state":31,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Shanghi Tongji Hospital (Tongji Hospital of Tongji University)","RECRUITING","Shanghai","620000","China",{"type":41,"coordinates":42},"Point",[43,44],121.45806,31.22222,{"lat":44,"lon":43},[47],{"name":29,"role":30,"phone":25,"phoneExt":31,"email":31},{"type":49,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[51],{"name":52,"class":53},"Shanghai Tongji Hospital, Tongji University School of Medicine","OTHER","100612022",false,"NCT07248176","Universal CAR-T Cell Therapy for MM","A Clinical Study on the Safety and Efficacy of Allogeneic CAR T Cells Targeting BCMA in the Treatment of Adult r\u002Fr Multiple Myeloma","Inclusion Criteria:\n\n1. Expected survival of at least 3 months;\n2. Subjects should have measurable disease that meets the IMWG 2016 criteria;\n3. Previously received at least two lines of prior anti-myeloma therapy ；\n4. Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；\n5. BCMA positive；\n6. ECOG score 0-1；\n7. No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. History of other malignant tumors;\n3. Active autoimmune diseases requiring immunotherapy;\n4. Previously received allogeneic stem cell transplantation;\n5. Previous use of CAR-T cells or other genetically modified T cell therapies;\n6. Previously received targeted BCMA therapy;\n7. Severe cardiovascular disease;\n8. Active infection;\n9. Positive virology test;\n10. Clinically significant central nervous system (CNS) diseases or pathological changes.","ALL","18 Years",{"count":63,"type":64},6,"ESTIMATED","INTERVENTIONAL",[67],"NA","This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r\u002Fr multiple myeloma.",[70,71,72],"Multiple Myeloma","Multiple Myeloma in Relapse","Multiple Myeloma, Refractory","2025-11-28",{"date":75,"type":76},"2025-12-01","ACTUAL",{"date":78,"type":76},"2025-04-10",{"date":80,"type":64},"2028-04-18",{"name":5,"class":6},1]